Drug intelligence / Profile preview

AFN1213

Development stage: Unknown
Lead developer: Hefei Afana Biotechnology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AFN1213 is an mRNA-based vaccine candidate developed by Hefei Alphana Biotech for the prevention of herpes zoster (shingles). The vaccine utilizes messenger RNA technology to encode a specific antigen of the varicella-zoster virus (VZV), typically the glycoprotein E (gE), to elicit a robust protective immune response. It is currently being evaluated in Phase 1 clinical trials in China, specifically targeting adults aged 40 years and older. The clinical evaluation focuses on the safety, tolerability, and preliminary immunogenicity of a two-dose regimen administered intramuscularly at months 0 and 2.

Targets

gE (VZV glycoprotein E)

Beyond the preview

Go deeper on AFN1213.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFN1213.

Explore the full profile